396 related articles for article (PubMed ID: 19840660)
21. Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry.
Worrall EE; Sudarisman ; Priadi A
Vaccine; 2009 Jun; 27(31):4161-8. PubMed ID: 19406183
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
23. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
[TBL] [Abstract][Full Text] [Related]
24. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
[TBL] [Abstract][Full Text] [Related]
25. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.
Shoji Y; Bi H; Musiychuk K; Rhee A; Horsey A; Roy G; Green B; Shamloul M; Farrance CE; Taggart B; Mytle N; Ugulava N; Rabindran S; Mett V; Chichester JA; Yusibov V
Vaccine; 2009 Feb; 27(7):1087-92. PubMed ID: 19100806
[TBL] [Abstract][Full Text] [Related]
26. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
27. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
Crevar CJ; Ross TM
Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
[TBL] [Abstract][Full Text] [Related]
28. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
[TBL] [Abstract][Full Text] [Related]
29. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness.
Bizanov G; Janakova L; Knapstad SE; Karlstad T; Bakke H; Haugen IL; Haugan A; Samdal HH; Haneberg B
Scand J Immunol; 2005 Jun; 61(6):503-10. PubMed ID: 15963044
[TBL] [Abstract][Full Text] [Related]
30. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus.
Szécsi J; Gabriel G; Edfeldt G; Michelet M; Klenk HD; Cosset FL
J Infect Dis; 2009 Jul; 200(2):181-90. PubMed ID: 19505256
[TBL] [Abstract][Full Text] [Related]
31. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.
Lalor PA; Webby RJ; Morrow J; Rusalov D; Kaslow DC; Rolland A; Smith LR
J Infect Dis; 2008 Jun; 197(12):1643-52. PubMed ID: 18513153
[TBL] [Abstract][Full Text] [Related]
32. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
[TBL] [Abstract][Full Text] [Related]
33. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
34. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.
Yang P; Duan Y; Zhang P; Li Z; Wang C; Dong M; Tang C; Xing L; Gu H; Zhao Z; Liu X; Zhang S; Wang X
PLoS One; 2012; 7(1):e30252. PubMed ID: 22279575
[TBL] [Abstract][Full Text] [Related]
35. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
[TBL] [Abstract][Full Text] [Related]
36. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
37. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
[TBL] [Abstract][Full Text] [Related]
38. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
[TBL] [Abstract][Full Text] [Related]
40. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
